Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin + Caelyx versus Caelyx alone in advanced-relapsed ovarian/primary peritoneal/fallopian tube cancer
2012-004808-34Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2013
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Trabectedin + Caelyx with Caelyx monotherapy (2 arms). Primary endpoint: Overall survival. Started Apr 2013; status: completed.
02
Drugs
trabectedinpegylated liposomal doxorubicin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2012-004808-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004808-34.